Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Apr 11:2013:214304.
doi: 10.1155/2013/214304. Print 2013.

Does Time between Imaging Diagnosis and Initiation of Radiotherapy Impact Survival after Whole-Brain Radiotherapy for Brain Metastases?

Affiliations

Does Time between Imaging Diagnosis and Initiation of Radiotherapy Impact Survival after Whole-Brain Radiotherapy for Brain Metastases?

Carsten Nieder et al. ISRN Oncol. .

Abstract

Aims. To evaluate whether reduced waiting time influences survival of patients treated with whole-brain radiotherapy (WBRT) for brain metastases. Materials and Methods. Retrospective intention-to-treat study including 110 patients treated with primary WBRT (typically 10 fractions of 3 Gy; no other treatment between diagnosis and WBRT). Uni- and multivariate tests were performed. Results. Median delay between imaging diagnosis and WBRT was 12 days (range 0-66 days). WBRT started within 1 week in 36%, during the second week in 28%, and during the third week in 18% of patients. No significant correlation between waiting time and survival was evident, except for one subgroup of patients. Those without extracranial metastases (potentially more threatened by worse intracranial disease control) survived for a median of 2.5 months from WBRT if waiting time was 2 weeks or longer as compared to 5.6 months if waiting time was shorter than 2 weeks (P = 0.03). The same correlation was seen if survival was computed from imaging diagnosis. Conclusion. If departmental resources are not sufficient to provide immediate WBRT within 2 weeks to all patients, those without extracranial metastases should be prioritised. This study did not address the impact of waiting time on quality of life or symptom palliation.

PubMed Disclaimer

References

    1. Rosenblatt E, Izewska J, Anacak Y, et al. Radiotherapy capacity in European countries: an analysis of the Directory of Radiotherapy Centres (DIRAC) database. The Lancet Oncology. 2013;14(2):e79–e86. - PubMed
    1. Lavergne MR, Johnston GM, Gao J, Dummer TJB, Rheaume DE. Variation in the use of palliative radiotherapy at end of life: examining demographic, clinical, health service, and geographic factors in a population-based study. Palliative Medicine. 2011;25(2):101–110. - PMC - PubMed
    1. Kong W, Jarvis CR, Sutton DS, Ding K, Mackillop WJ. The use of palliative whole brain radiotherapy in the management of brain metastases. Clinical Oncology. 2012;24(10):e149–e158. - PubMed
    1. Tsao MN, Rades D, Wirth A, et al. International practice survey on the management of brain metastases: third international consensus workshop on palliative radiotherapy and symptom control. Clinical Oncology. 2012;24(6):e81–e92. - PubMed
    1. Rades D, Kieckebusch S, Lohynska R, et al. Reduction of overall treatment time in patients irradiated for more than three brain metastases. International Journal of Radiation Oncology, Biology, Physics. 2007;69(5):1509–1513. - PubMed

LinkOut - more resources